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Peptide-based therapeutics have significant potential for use in a variety of clinical applications 
ranging from cancer therapy to promotion of cardiovascular health. However, the efficacy of these 
approaches is limited due to poor cellular uptake and peptide sequestration within endo-lysomal vesicles 
that are trafficked for exocytosis or lysosomal degradation. The drug delivery platform described herein 
provides a means to overcome these barriers through the use of cell-permeant, pH-responsive nano-
polyplexes that significantly enhance cell internalization and facilitate endosomal escape of a cationic, 
therapeutic peptide. A reproducible method to synthesize electrostatically complexed nanoparticles 
containing a therapeutic peptide and a pH-responsive polymer has been developed and optimized to yield 
nano-polyplexes of approximately 100 nm in diameter. These polyplexes display pH-dependent 
membrane disruption ideal for endosomal escape, which was verified through microscopic analysis of 
cellular uptake and intracellular trafficking. The polyplexes were found to have significantly enhanced 
bioactivity in reducing inflammatory cytokine production in stimulated human vascular smooth muscle 
cells in vitro compared to the peptide alone (p<0.05). Furthermore, flow cytometric analysis revealed that 
these polyplexes significantly enhanced cellular uptake and intracellular half-life compared to the peptide 
alone (p<0.05). This promising platform technology provides a novel method to effectively enhance 
cytosolic delivery of cationic therapeutic peptides and demonstrates a potentially high-impact therapeutic 
approach to improving graft patency in vascular bypass grafting applications. 
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CHAPTER I 
 
INTRODUCTION 
 
Vein Graft Failure 
 Cardiovascular disease (CVD) is the leading cause of death in the United States, with coronary 
heart disease responsible for more than 50% of CVD-related mortality causing 1 of every 6 deaths 
[1]. In terms of financial burden, the direct and indirect cost of coronary heart disease in the US were 
~$200 billion in 2009, with a projected price increase of 100% between 2013 and 2030 [1] Coronary 
artery bypass grafting with autologous conduits remains the standard treatment for multi-vessel 
coronary heart disease. However, almost half of saphenous vein grafts fail within the first 18 months 
due to intimal hyperplasia (IH) [2]. One of the underlying causes of IH is activation of MAPKAP 
Kinase II (MK2) signaling in vascular smooth muscle cells (VSMCs), which occurs due to 
environmental and mechanical stresses experienced by the graft during surgical resection and 
transplantation[3]. MK2 activation results in vasoconstriction and pathological VSMC proliferation, 
migration, and excess ECM production that result in graft occlusion. These effects are primarily a 
result of the downstream phosphorylation of heat shock protein 27 (HSP27) by activated MK2, which 
stimulates the release of inflammatory cytokines and chemotactic agents from endogenous vascular 
cells [4-6] (See Fig. 1). A variety of small molecule inhibitors of MK2 exist, but they lack specificity 
and none have been approved  by the FDA [7]. In contrast, Hayess and Benndorf developed a highly 
specific peptide antagonist of MK2 [8], and a previous study suggests that intracellular delivery of 
peptidic MK2 inhibitor can reduce vasoconstriction and subsequent IH in human saphenous vein [4], 
but the efficacy of this approach is limited due to limited cellular uptake and peptide sequestration 
within endo-lysosomal vesicles that are trafficked for exocytosis or lysosomal degradation[9].  
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Figure 1 - P38 MAPK signaling cascade: that is activated in VSMCs during surgical 
resection and transplantation resulting in a pathological VSMC phenotype. 
 
Peptide Delivery Barriers 
The therapeutic potential of peptides, proteins, and antibodies in applications ranging from 
cancer treatments to vascular pathologies has become more apparent as the fundamental etiology of 
these disease states becomes more comprehensively characterized [10-16]. However, major in vivo 
barriers exist to effective intracellular delivery of peptide-based, biomacromolecular therapeutics for 
specific applications: proteolysis of the peptide in the in vivo environment prior to cellular 
internalization, circumvention of non-specific binding and/or side-effects, translocation across the 
cellular membrane, escape from the intracellular endo-lysosomal and exocytosis traffic king 
pathways, and achieving a therapeutically-relevant peptide dose within the intracellular micro-
environment where the therapeutic target is located (see fig. 2) [9, 17-19]. A variety of methods have 
been investigated to address these delivery barriers ranging from the utilization of drug delivery 
vehicles that improve proteolytic resistance and in vivo half-life [20-22] to the use of electroporation, 
or cell-penetrant/fusogenic peptides to increase cell internalization of biomacromolecular therapeutics 
[23-25]. In addition to these approaches, the study and use of colloidal drug carriers such as 
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liposomes, micelles, and nanoparticles to deliver biomacromolecular therapeutics has increased 
dramatically in the past decade [26-28].  
 
Figure 2 - Intracellular peptide delivery barriers: 1) Biomacromolecular therapeutics like 
peptides must first translocate the cellular membrane and become internalized in the cell 2) 
Once internalized, the therapeutic must escape from the endo-lysosomal pathway or 
consequently face degradation in lysosomes and/or trafficking for exocytosis out of the cell 3) 
Finally, if a drug delivery vehicle is utilized to deliver the therapeutic then the vehicle must 
contain an inherent mechanism to release the therapeutic in order to avoid steric hindrance of 
bioactivity in the cytosol. Figure adopted with permission from [29]. 
 
These colloidal drug carriers are attractive because they can be modified to be multi-functional in 
terms of containing targeting moieties [30], cell penetrating and/or fusogenic peptides [31, 32], and 
environmentally responsive ‘smart’ polymers that can facilitate escape from trafficking through the 
endo-lysosomal pathway [33-35]. Despite the advances made in overcoming these delivery barriers, 
substantial limitations still exists in terms of drug carriers that simultaneously address the key delivery 
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barriers of stability, cellular uptake, escape from the endo-lysosomal pathway, and an effective 
means to ‘un-package’ or release the desired therapeutic into the proper micro-environment. 
 
Approach 
The delivery requirements for intracellular-acting biomolecules like peptides are more 
rigorous because upon endocytosis, the predominant fate is enzymatic degradation in lysosomes or 
endosomal recycling and subsequent exocytosis from the cell. Here, we describe a novel method to 
form nanometer-sized electrostatic complexes that contain a therapeutic inhibitory peptide (i.e. MK2i) 
and a “smart” polymer component. This ‘smart’ polymer can recognize environmental changes in pH, 
and thus can respond to the proton pump-mediated acidification of endosomal vesicles to release the 
therapeutic payload while simultaneously disrupting the endosomal membrane to allow for cytosolic 
peptide delivery.  This simple yet innovative approach to intracellular peptide delivery may enable a 
new level of pharmaceutical breadth and specificity that would overcome many of the drug delivery 
barriers that biomacromolecular drugs face, allowing for manipulation of intracellular targets that were 
previously considered “un-druggable”. The majority of peptide-based therapeutics solely rely on the 
use of a cell penetrating peptide sequence to enhance uptake, but they do not include an inherent 
mechanism to escape from trafficking through the endo-lysosomal pathway. Most of these cell 
penetrating peptides are cationic in nature and are typically rich in positively-charged amino acid 
residues [29], making biologic drugs containing cell penetrating peptide sequences well-suited to 
electrostatic complexation with anionic polymer-based carrier systems that can facilitate endosomal 
escape. The use of environmentally-responsive ‘smart’ polymers in conjunction with techniques to 
enhance cellular uptake would result in optimized payload delivery to the intracellular micro-
environment where the therapeutic target is located; The innovative combination of endosomolytic 
“smart” polymer technology and cell penetrant peptides provides a platform for the enhanced 
intracellular delivery of peptide-based therapeutics for a wide range of medical applications. 
Here, we introduce a robust approach for the intracellular delivery of a peptide inhibitor of 
MK2 to modulate VSMC phenotype. This new platform incorporates an anionic “smart” polymer that 
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can form electrostatic complexes with an optimized, highly-specific cationic therapeutic peptide (see 
fig. 3). 
 
Figure 3 – Approach to achieve intracellular MK2i delivery: Nanopolyplexes composed of 
a cell-penetrant, cationic therapeutic peptide and an anionic ‘smart’ polymer that respond to 
the increase in acidity upon endosomal uptake to facilitate endosomal escape and release of 
the peptide into the cytoplasm. 
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CHAPTER II 
 
ENHANCED INTRACELLULAR PEPTIDE DELIVERY WITH PH-RESPONSIVE, ENDOSOMOLYTIC 
NANO-POLYPLEXES TO MODULATE VASCULAR SMOOTH MUSCLE CELL BEHAVIOR 
 
Introduction 
 The clinical potential of peptide-based therapeutics has increased over the past few decades, 
and these therapeutics continue to be extensively utilized as lead compounds in the drug discovery 
process to elucidate the mechanisms of molecular recognition and target-specificity [36]. Despite the 
advantages offered by peptide based therapeutics (biomimetic, increased target-specificity, and high 
potency), the shortcomings of poor bioavailability, limited membrane permeability, and metabolic 
instability result in a clinical preference for low-cost small-molecule drugs characterized by reduced 
target-specificity that can result in non-specific side effects in humans [12]. The current work focuses 
on development of a platform technology to be used for the enhanced intracellular delivery of 
therapeutic peptides to overcome these shortcomings. 
 An effective means to facilitate endosomal escape has been the primary limitation to the 
success of peptide based therapeutics in clinical applications. As aforementioned, a variety of 
approaches have been developed to facilitate endosomal escape, specifically pH-responsive “smart” 
polymers that can respond to the environment encountered in the endosomal pathway [37]. 
Controlled polymerization techniques, specifically reversible addition-fragmentation chain transfer 
(RAFT) polymerization, offer a promising approach to designing synthetic polymers that are 
monodisperse, and contain spatially-defined functionalities [38, 39], and these techniques can be 
used to synthesize well-defined, pH-responsive polymers that can be utilized as endosomolytic 
agents in drug delivery applications [9]. 
 By enhancing the cytosolic delivery of intracellular-acting peptides the required dose can be 
minimized, reducing cost and maximizes therapeutic efficacy. Furthermore, by optimizing the 
bioavailability of the therapeutic peptide in the micro-environment in which it is active may also result 
in an increase in the duration of therapeutic efficacy [40]. Recently, the use of pH-responsive 
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polymers has been reported to enhance intracellular delivery of bio-macromolecular therapeutics, 
ranging from the intracellular delivery of pro-apoptotic peptides for anti-cancer therapies [9, 27, 29] to 
the enhanced vaccine performance of antigen-polymer bioconjugates [33, 41]. However, these 
approaches typically involve complex conjugation chemistry necessitating extra purification steps that 
result in high-cost and low yields. Consequently, there exists a need to develop a simplified synthetic 
method to synthesize pH-responsive, endosomolytic drug delivery vectors for peptide-based 
therapeutics.  
 The current study pursues a novel approach to the synthesis of endosomolytic nano-
polyplexes for the intracellular delivery of cationic peptides. This work verifies the synthesis and 
efficacy of electrostatic complexes containing a MK2 inhibitory peptide for the modulation of VSMC 
phenotype and demonstrates the potential of this platform to prevent intimal hyperplasia and improve 
graft patency in vascular grafting applications.  
 
Methods 
  
Materials 
All reagents were purchased from Sigma and were of analytical grade unless otherwise 
stated. PD10 desalting columns were purchased from GE healthcare. Diethyl propylmalonate was 
purchased from Alfa Aesar (Ward Hill, MA). All monomers were filtered through a basic alumina 
column to remove inhibitors prior to use in polymerizations. Dioxane was distilled prior to use in 
polymerizations.  2,2’-Azobis(2-methylpropionitrile) (AIBN) was recrystallized twice with methanol. 
 
Synthesis of 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid (ECT) 
The RAFT chain transfer agent ECT was synthesized following protocols previously 
described by Convertine et al. [42] and adapted from Moad et al. [43]. Briefly, Ethanethiol (76 mmol, 
4.72 g) was reacted with carbon disulfide (79 mmol, 6.0 g) in the presence of sodium hydride (79 
mmol, 3.15 g) in diethyl ether for 1h. The resulting sodium S-ethyl trithiocarbonate was further reacted 
with iodine (25 mmol, 6.3 g) to obtain bis(ethylfulfanyl-thiocarbonyl) disulfide, which was further 
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refluxed with 4,4’-azobis(4-cyanopentanoic acid) in ethylacetate for 18 h.  The crude ECT was 
purified by column chromatography using silica gel as the stationary phase and a gradient of ethyl 
acetate:hexane (40:60 to 70:30) as the mobile phase. 
1
H NMR (400MHz, CDCl3):  1.36 t (SCH2CH3); 
 1.88 s (CCNCH3);  2.3–2.65 m (CH2CH2);  3.35 q (SCH2CH3). 
 
Synthesis of 2-propylacrylic acid (2-PAA) 
The synthesis of PAA was adapted from existing methods developed by Ferrito et al. [44]. 
Briefly, diethyl propylmalonate (200 mmol, 40.45 g) was stirred in 1M KOH in 95% ethanol and 
acidified with HCl to yield 2-carbopropoxybutyric acid, which was reacted with diethylamine (200 
mmol, 14.62 g) and formalin (200 mmol, 16.11 g) at room temperature for 24h, followed by reflux at 
60°C for 8 hours.  Following acidification with sulfuric acid, the resulting 2-propylacrylate was 
extracted 3x with diethyl ether and dried over magnesium sulfate. The pure 2-propylacrylate was then 
refluxed in 2M KOH for 20 h to yield   2-propyl acrylic acid, which was extracted 3x with diethyl ether, 
dried, and vacuum distilled under vacuum to yield a colorless oil. 
1
H NMR (400 MHz, CDCl3)  0.97 t 
(CH3CH2);  1.55 m (CH3CH2CH2);  2.31 t (CH3CH2CH2);  5.69-6.32 q (CH2=C);  12 s (CCOOH). 
  
Synthesis and Characterization Poly(propylacrylic acid) (PPAA) and Poly(acrylic acid) (AA) 
The ECT chain transfer agent (CTA) was utilized in the RAFT polymerization of a poly(2-
propylacrylic acid) homopolymer (PPAA) that was carried out in bulk under a nitrogen atmosphere at 
70°C for 48 hours using AIBN as the free radical initiator. The reaction mix was put through three 
freeze-vacuum-thaw cycles and purged with nitrogen for thirty minutes prior to polymerization. The 
molar ratio of CTA to AIBN was 1 to 1 and the monomer to CTA ratio was set so that a molecular 
weight of 25,000 g/mol would be achieved at 100% conversion. Following polymerization, the 
resultant polymer was dissolved in DMF and precipitated into ether 5 times before drying overnight in 
vacuo. The RAFT polymerization of a poly(acrylic acid) homopolymer (AA) was carried out in distilled 
dioxane under a nitrogen atmosphere at 70°C for 18 hours using AIBN as the free radical initiator and 
ECT as the CTA. The reaction mix was purged with nitrogen for thirty minutes prior to polymerization. 
The molar ratio of CTA to AIBN was 5 to 1 and the monomer to CTA ratio was set so that a molecular 
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weight of 8,000 g/mol would be achieved at 100% conversion. Following polymerization, the resultant 
polymer was dissolved in dioxane and precipitated into ether 5 times before drying overnight in 
vacuo.  Gel permeation chromatography (GPC, Agilent) was used to determine molecular weight and 
polydispersity (Mw/Mn, PDI) of the PPAA and AA homopolymers using HPLC-grade DMF containing 
0.1% LiBr at 60°C as mobile phase. Molecular weight calculations were calculated with ASTRA V 
software (Wyatt Technology) and were based on calculated dn/dc values for PPAA determined 
through injection of serial dilutions of the polymer in conjunction with off-line refractive index 
monitoring (calculated PPAA dn/dc = 0.087 mL/g, calculated PAA dn/dc = 0.09 mL/g ).  
 
Synthesis of YARA-MK2i and YARA Peptides 
A cell penetrant MK2 inhibitor peptide (YARA-MK2i, sequence YARAAARQARA-
KALARQLGVAA MW = 2283.67) and a control cell penetrating peptide (YARA, sequence 
YARAAARQARA MW = 1204.37) were synthesized on a PS3 3 channel serial peptide synthesizer 
(Protein Technologies, Inc. Tucson, AZ) utilizing standard Fmoc Chemistry. N-methylpyrrolidone 
(NMP, Fischer Scientific) was utilized as a solvent in all peptide syntheses. HCTU was used as an 
activator (Chempep, Wellington, FL) in the presence of N-methylmorpholine. All amino acids were 
double coupled in order to maximize yield and purity. Peptides were cleaved/deprotected in Reagent 
B: TFA/Phenol/H2O/triisopropylsilane (88/5/5/2).  Successful peptide synthesis was verified through 
LC-MS analysis on a Waters Synapt ESI-MS. Peptides were then further purified by reverse phase 
HPLC on a Waters 1525 binary HPLC pump outfitted with an extended flow kit, a Waters 2489 
UV/Visible detector and a phenomenex Luna C18(2) AXIA packed column (100A, 250 x 21.2  mm, 5 
micron). A) HPLC grade water with 0.05% formic acid and B) HPLC grade acetonitrile were used as 
the mobile phases and the peptide was purified utilizing a 90% A to 100% B gradient over 25 minutes 
(16 mL/min). Acetonitrile was removed from purified fractions with a rotary evaporator and the purified 
fractions were then frozen, lyophilized, and peptide purity was verified through electrospray ionization 
mass spectrometry (ESI-MS). 
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Synthesis and Characterization of Polyplexes 
Poly(propylacrylic acid) was dissolved in 1 M NaOH and diluted into a phosphate buffer (pH 
8) to obtain a stock solution. Purified YARA-MK2i peptide was dissolved in phosphate buffer (pH 8). 
The defined pH of the stock solutions was selected as an optimal balance between the pKa values of 
the primary amines present on the YARA-MK2i peptide (i.e. NH3
+
, pKa ~ 9-12 depending on amino 
acid) and the pKa values of the carboxylic acid moieties present on the polymer backbone (i.e. COO
-
, 
pKa ~ 6.7). The YARA-MK2i peptide and PPAA polymer were mixed at a range of charge ratios 
([NH3
+
]/[COO
-
]) from 10:1 to 1:10 to form polyplexes (see fig. 4). The resulting polyplexes were 
syringe filtered through 0.45 µm PTFE filter and the hydrodynamic radius and ζ-potential were 
characterized by dynamic light scattering (DLS) analysis in a Malvern zetasizer Nano-ZS with a 
reusable dip cell kit (Malvern Instruments Ltd., Worcestershire, U.K.). 
 
Figure 4 – Polyplex nanoparticle synthesis scheme: Mixing the YARA-MK2i fusion 
peptide and pH-responsive, endosomolytic polymer at the appropriate pH (between the pKa 
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values of the primary amines present on the peptide and the carboxylic acid groups present 
in the polymer) results in the formation of electrostatic complexes, or ‘polyplex’ nanoparticles. 
A CR of 1:3 was then chosen as the optimal formulation and used in subsequent cell studies. 
In order to verify the sizes indicated by DLS analysis, polyplexes at a charge ratio of 1:3 were 
visualized through transmission electron microscopy (TEM) imaging. TEM samples were prepared by 
inverting carbon film-backed copper grids (Ted Pella) onto a 20 µL droplet of aqueous polyplex 
suspensions (1 mg/mL) and blotted dry. All samples were then inverted onto a 20 µL droplet of 3% 
Uranyl Acetate and allowed to stain for 2 min. After blotting the sample dry, samples were desiccated 
in vacuo for 2 h prior to imaging on a Philips CM20 system operating at 200 kV. Images were 
collected using a CCD camera with AMT Image capture Engine software (Advanced Microscopy 
Techniques, Danvers, MA).  PH-dependent size changes of polypexes at a CR of 1:3 were then 
quantified by DLS analysis at various pH values (i.e. pH 7.4, 6.8, 6.2, and 5.6).  
 
PH-Dependent Membrane Disruption Hemolysis Assay 
In order to assess the polyplexes’ potential for enhancing endosomal escape, a red blood cell 
hemolysis assay was utilized as previously described [45]  to measure the capacity of polyplexes to 
cause pH-dependent disruption of lipid bilayers. Briefly, following approval by Vanderbilt Medical 
Center’s Institutional Review Board, whole human blood from an anonymous donor was drawn and 
plasma was aspirated following centrifugation of the red blood cells. The remaining erythrocytes were 
washed three times with 150 mM NaCl and re-suspended into phosphate buffers corresponding to 
physiologic (pH 7.4), early endosome (pH 6.8), early/late endosome (pH 6.2), and late 
endosome/lysosomal (pH 5.8) environments. The polyplexes and peptides (1-40 μg/mL), PBS 
(negative control), or 1% Triton X-100 (positive control) was added to the erythrocyte suspensions 
and incubated at 37 °C for 1 hour. Intact erythrocytes were pelleted via centrifugation, and 
supernatant was carefully transferred to a new 96-well plate. The hemoglobin content within the 
supernatant was then measured via absorbance at 541 nm. Percent hemolysis was determined 
relative to Triton X-100 and PBS controls. 
 
Cell Culture 
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Primary human coronary artery vascular smooth muscle cells (HCAVSMCs) were obtained 
from Lonza; HCAVSMCs were cultured in Vascular cell basal medium (ATCC) supplemented with 5% 
FBS, human basic fibroblast growth factor (bFGF, 5 ng/mL), human Insulin (5µg/mL), Ascorbic acid 
(50 µg/mL), L-glutamine (10 mM), and human epidermal growth factor (EGF, 5 ng/mL), and 1% 
penicillin-streptomycin.  
 All cultures were maintained in 75cm
2
 polystyrene tissue culture flasks at 37°C, 5% CO2 
environment with cell culture media refreshed every other day. All cells were seeded at a density of 
20,000-40,000 cells/cm
2
, as required by the specific experiment, and allowed to grow to 80-90% 
confluence prior to being harvested/passaged. Only cells from early passages (numbers 3-7) were 
used in experiments. 
 
Polyplex Cytotoxicity 
The CytoTox-ONE Homogenous Membrane Integrity assay (Promega) was used to assess 
the cytotoxicity of peptide and polyplex treatments according to the manufacturer’s instructions. 
Briefly, HCAVSMCs from early passage were grown to 80-90% confluence in a 75 cm
2
 tissue culture 
flask in a 37°C/5% CO2 incubator prior to harvest. 200 µL of cell suspension (at 10,000 cells/well) was 
seeded onto 96-well plates to yield an approximate 70% confluence per well. Cells were allowed to 
adhere to the plate overnight. Cells were treated with polyplexes or peptides alone and incubated for 
2 hours. Following treatment, cells were aspirated and 200 µL of fresh medium was added to each 
well. After 24 hours of incubation in fresh media cells were washed 2x with PBS and re-suspended in 
100 µL lysis buffer. Each well was then supplemented with 100 µL Lactate dehydrogenase (LDH) 
substrate and incubated at RT for 10 minutes prior to the addition of 50 µL stop solution. LDH-
induced fluorescence (excitation 550 nm, emission 600 nm) was then quantified with a TECAN 
Infinite M1000 Pro plate reader and used to determine cell viability compared to untreated control 
groups. 
 
Inflammatory Cytokine Analysis 
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In order to evaluate the ability of polyplexes to inhibit Interleukin-6 production, HCAVSMCs 
were cultured and seeded onto a 96-well plate using the methods described in the LDH cytotoxicity 
assay above. Cells were treated with 20 ng/mL tumor necrosis factor-α (TNFα) for 4 hours followed 
by treatment with polyplexes or peptides alone for 2 hours. Following treatment, each well was 
aspirated and supplemented with fresh medium. After 12 and 24 hours, 100 µL of supernatant was 
collected and frozen at -80°C until cytokine analysis could be performed. 
Similarly, to evaluate the ability of polyplexes to inhibit TNFα production, HCAVSMCs were 
cultured and seeded onto a 96-well plate using the methods described in the LDH cytotoxicity assay 
above. Cells were treated with 10 μM ANG II for 4 hours followed by treatment with polyplexes or 
peptides alone for 2 hours. Following treatment, each well was aspirated and supplemented with 
fresh medium. After 12 and 24 hours, 100 µL of supernatant was collected and frozen at -80°C until 
cytokine analysis could be performed. 
Human IL-6 (cat # 900-K16) and Human TNFα (cat # 900-K25) ELISA development kits 
(Peprotech; Rocky Hill, NJ) were used to measure cytokine levels in supernatant collected from 
treated cells. For both assays 9 standards were prepared according to the manufacturer’s protocol. 
40 µL of supernatant was diluted with 60 µL diluent; quadruplicates of each sample were used. 
Absorbance at 405 nm with wavelength correction at 650 nm was monitored for 1 hour with readings 
taken every 5 minutes. Concentrations of IL-6 and TNFα were determined through extrapolation from 
a 4 parameter logistic fit of the standard curve. All data were then normalized to cell viability 
determined through a LDH-based cytotoxicity assay. Data are expressed as mean ± SEM. 
 
Microscopic Analysis of Cellular Uptake and Trafficking 
An amine-reactive 5(6) carboxyfluorescein succinimidyl ester was dissolved in DMSO and 
mixed at a 1 to 1 molar ratio with the YARA-MK2i peptide in 100 mM sodium bicarbonate buffer (pH = 
8.3). Unreacted fluorophore and organic solvent were removed using a PD-10 miditrap G-10 
desalting column, and the fluorescently labeled peptide was lyophilized. After accounting for the loss 
of a primary amine from the peptide due to conjugation of the fluorophore, PPAA polymer or AA 
polymer and fluorescently labeled YARA-MK2i peptide were mixed at a CR of [NH3
+
]/[COO
-
] = 1:3 to 
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form polyplexes and syringe filtered through a 0.45 µm PTFE filter. Fluorescent polyplex size and 
zeta potential were measured by DLS analysis. Fluorescently-labeled peptide alone or fluorescent 
polyplexes were applied to HCAVSMCs grown on 8-well chambered microscope slides at a 
concentration of 25 µM YARA-MK2i or YARA in DMEM media supplemented with 1% FBS and 1% 
P/S. Cells were pre-incubated in low serum growth media for 24 hours to cause quiescence. Cells 
were then treated in quadruplicate for 2 hours, washed with PBS -/-, and the medium was refreshed. 
Cells were then incubated for an additional 0, 2, 10, or 22 hours. For the final two hours of incubation 
or treatment 50 nM Lysotracker Red DND-99 was added to each well in order to visualize acidic 
endo/lysosomal vesicles within cells. After incubation, cells were washed with 0.1% trypan blue for 1 
minute to quench extracellular fluorescence followed by 2 additional washes with PBS -/-. Cells were 
then imaged using a LSM 710 META fluorescence microscope with ZEN imaging software (Carl Zeiss 
Thornwood, NY).  
All images were processed using ImageJ and Mander’s coefficients for quantifying co-
localization were calculated using Just Another Colocalization Plugin (JACoP) [46]. Mander’s 
coefficients calculated from 3 separate images for each treatment group were averaged to obtain 
average colocalization values. Pixel intensity thresholds were set for both the green (fluorescein) and 
red (lysotracker) channels so that background pixels were excluded form colocalization calculations. 
 
Flow Cytometric Quantification of Cellular Uptake and Intracellular Peptide Half-life 
HCAVSMCs were grown to 80-90% confluence, harvested, and seeded at 40,000 cells/mL in 
a 24 well tissue culture plate. Fluorescent YARA-MK2i and polyplexes were synthesized as noted 
above in the microscopic analysis of cellular uptake section and HCAVSMCs were quiesced in low 
serum growth media (1% FBS, 1% P/S in DMEM) for 24 hours to ensure that cellular uptake and 
retention was not affected by actively proliferating cells. Cells were then treated in triplicate with 
fluorescently-labeled peptide alone or fluorescent polyplexes at a concentration of 25 µM YARA-MK2i 
for 2 hours, washed with PBS -/-, and the medium was refreshed. Cells were then incubated for an 
additional 0, 2, 10, 22, or 46 hours. Cells were then washed with PBS -/-, trypsinized, and re-
suspended in 0.1% Trypan blue in PBS (-/-) for flow cytometric analysis on a BD (Franklin Lakes, NJ) 
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FACSCalibur system utilizing BD Cellquest Pro (version 5.2) acquisition software. The FL1 channel 
(emission filter at 530 ± 15 nm) was used to quantify the FAM-based fluorescence from each cell. 
Average fluorescence intensities for each time point were averaged and a half-life for intracellular 
fluorescence was calculated by fitting an exponential curve to the data. 
 
Statistical Analysis 
Statistical analysis was performed with one-way ANOVA followed by a Tukey test to compare 
experimental groups. Analyses were done with Minitab 16 software (State College, PA) or Microsoft 
Excel. Statistical significance was accepted within a 95% confidence limit. Results are presented as 
arithmetic mean ± SEM graphically. 
 
Results 
 
Polymer Synthesis and Characterization 
4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid (ECT) was synthesized as 
previously described [Convertine, 2009 #34].  2-propyl acrylic acid (PAA) was synthesized using 
established methods [Ferrito M, 1992 #36].  RAFT polymerization was used to synthesize a 
poly(propylacrylic acid) homopolymer [PPAA, Mn = 22,010 g/mol, PDI = 1.47 (GPC) Appendix A]. 
1
H-
NMR was used to verify molecular weight determination yield by GPC analysis (Mn =  21,950, 
Appendix B). Similarly, RAFT polymerization was used to synthesize a poly(acrylic acid) 
homopolymer (AA) with a targeted molecular weight of 8,000 g/mol [Mn = 10,830, PDI = 1.27 (GPC) 
Appendix A] and molecular weight determined by GPC was verified by 
1
H-NMR (Mn = 7,640, 
Appendix B). 
 
Peptide Synthesis and Purification 
The Purity of the HPLC-Purified YARA-MK2i and YARA peptides was verified through 
electrospray ionization mass spectrometry (YARA-MK2i MW = 2283.67 g/mol, YARA MW = 1204.37 
figs. 5A-B). 
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Figure 5 – YARA-MK2i and YARA Mass Spectra: Electrospray-ionization mass 
spectrometry (ESI-MS) mass spectrum for A) the HPLC-purified YARA-MK2i fusion peptide 
(sequence: YARAAARQARA-KALARQLGVAA, MW = 2283.67 g/mol) and B) the YARA cell 
penetrating peptide (sequence: YARAAARQARA, MW = 1204.37 g/mol). Each spectrum 
shows multiple peaks, all of which correspond to the full peptide weight. 
 
 
 
Polyplex Synthesis and Characterization 
Polyplexes were formed by mixing the pH-responsive PPAA polymer with the YARA-MK2i 
peptide in a buffered solution with a defined pH between the pKa values of the carboxylic acid groups 
and primary amines present on the polymer and peptide, respectively (pH 8). The polymer and 
peptide were mixed at a range of charge ratios from [NH3
+
]/[COO
-
] = 10:1 to [NH3
+
]/[COO
-
] = 1:10. 
DLS analysis revealed that the charge ratio significantly affected polyplex formation in terms of size 
and zeta potential, with only a narrow range of charge ratios yielding a unimodal size distribution of 
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nanoparticles (i.e. charge ratios of 1:2 and 1:3, see fig. 6A). It should also be noted that a visible 
precipitate formed upon mixing at charge ratios between [NH3
+
]/[COO
-
] = 2:1 to 1:1.5. After 
considering the size distribution for all formulations, a charge ratio of 1:3 was chosen as the optimal 
formulation as this ratio consistently yielded a unimodal size distribution with minimal particle size and 
polydispersity (hydrodynamic diameter = 118.8.9 ± 26.76 nm, ζ = -11.9 ± 3.18 mV). Furthermore, 
fluorescent polyplexes prepared with a fluorescently-labeled YARA-MK2i peptide and control 
polyplexes formulated with the YARA cell penetrating peptide alone (subsequently herein referred to 
as CPP polyplexes), both at a charge ratio of 1:3, yielded similar size distributions to the YARA-MK2i 
polyplexes. As expected, the ζ-potential decreased as the ratio of polymer to peptide increased, with 
a charge ratio of [NH3
+
]/[COO
-
] = 2:1 yielding a near neutral ζ-potential (see fig. 6B). Furthermore, 
both the fluorescently labeled polyplexes and the control CPP polyplexes were found to have similar 
ζ-potentials to the YARA-MK2i polyplex at a charge ratio of 1:3. 
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Figure 6 – Polyplex characterization summary: A) Table of the sizes of polyplexes 
prepared at different charge ratios ([NH3
+
]/[COO
-
]) determined by DLS analysis. Asterisks (*) 
indicate size distributions with multiple peaks present. 1:3 (FAM) polyplexes were formulated 
with a carboxyfluorescein fluorophore-labeled YARA-MK2i peptide to use in cellular uptake 
studies. 1:3 (CPP) polyplexes were formulated with the cell penetrating peptide sequence 
YARA (i.e. no therapeutic MK2 inhibitory peptide) to use as a peptide control. 1:3 (AA) 
polyplexes were formulated with an acrylic acid polymer that does not have a pH response in 
the desired pH range as a vehicle control. B) ζ-potential of polyplexes prepared at different 
charge ratios ([NH3
+
]/[COO
-
]) determined on a Zetasizer Nano ZS. Values shown are an 
average of at least 3 independent measurements. 
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 In order to verify the DLS results, uranyl acetate-stained polyplexes (at a charge ratio = 1:3) 
were imaged using transmission electron microscopy. TEM images revealed particle sizes in 
agreement with results from DLS analysis (see fig. 7A-C). 
 
Figure 7 – DLS and TEM analysis of polyplex morphology: Size distribution and 
representative TEM images of (A) PPAA polyplexes, (B) AA polyplexes, and (C) CPP 
polyplexes. All polyplexes were prepared at a charge ratio of [NH3
+
]/[COO
-
] = 1:3 (Scale bars 
= 100 nm). 
 
In order to verify that the pH-responsive behavior of the PPAA polymer is maintained when 
electrostatically complexed with the CPP-MK2i peptide the pH-dependent size changes of polyplexes 
at a charge ratio of 1:3 were measured by DLS. Results indicate that as the pH approaches the pKa 
value (6.7) of the carboxylic acid groups on the PPAA polymer that these groups become protonated, 
resulting in neutralization of the polymer and cationic, electrostatic repulsion of the peptide and 
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subsequent dissociation of the polyplex into polymer and peptide unimers (see fig. 8B-E). Red blood 
cell hemolysis was used to measure pH-dependent membrane disruption activity of polyplexes at pH 
values mimicking physiologic (pH 7.4), early endosome (pH 6.8), early/late endosome (pH 6.2), and 
late endosome/lysosomal (pH 5.8) environments (see fig. 8A). At physiologic and even early 
endosomal pH, no significant red blood cell membrane disruption was observed even at polymer 
concentrations as high as 40 μg/mL. However, as the pH was lowered to late endosomal values, a 
significant increase in hemolysis was observed, with greater membrane disruption at pH 5.8 
compared to 6.6. The hemolytic behavior of the polymer was directly proportional to polymer 
concentration, with over 90% erythrocyte lysis occurring at 40 μg/mL polymer in pH 5.8 buffer. This 
switch-like transition to a membrane disruptive conformation at late endosomal pH combined with 
negligible membrane disruptive activity in the physiologic pH range demonstrates the desired 
functionality of the polyplexes and further indicates their potential as non-toxic, endosomolytic 
intracellular delivery vehicles. Interestingly, the polyplexes demonstrated less hemolytic capacity than 
the pH responsive polymer alone, indicating that the formation of an electrostatic complex with the 
YARA-MK2i peptide slightly masks the membrane-disruptive activity of the polymer. This finding is 
consistent with the pH-dependent size changes monitored by DLS, which evinced polyplex 
dissociation at early endosomal pH values (i.e. pH 6.8), indicating that as the endosomal pH 
decreases the polyplexes will first dissociate and subsequently disrupt the endosomal membrane. 
This behavior is advantageous in that it effectively “un-packages” the therapeutic peptide from the 
electrostatic complexes prior to cytoplasmic release, ensuring that peptide bioactivity is not hindered 
due to steric hindrance from the pH-responsive polymer. 
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Figure 8 – Polyplex pH-responsive behavior: (A) PH-dependent hemolysis of polyplexes 
prepared at a charge ratio of [NH3
+
]/[COO
-
] = 1:3. Significant hemolysis was demonstrated at 
pH values representative of early to late endosomal vesicles (i.e. pH < 6.8), whereas no 
significant hemolysis was seen at a physiologic pH of 7.4. AA polyplexes did not show any 
significant hemolysis at any pH value tested (data not shown). PH-dependent size changes of 
polyplexes prepared at a charge ratio of [NH3
+
]/[COO
-
] = 1:3 were analyzed through DLS 
analysis. (B) Polyplexes at PH 7.4 show a unimodal size distribution. (C) Upon decreasing 
pH polyplexes begin to dissociate into individual fusion peptide and polymer unimers as 
shown in (D) and (E) respectively. 
 
 
In Vitro Analysis of Polyplex Biocompatibility and Bioactivity  
In order to assess the in vitro therapeutic efficacy and cytocompatibility of polyplexes 
compared to the CPP-MK2i peptide alone, TNFα and ANG II-stimulated HCAVSMCs were treated 
with a range of polyplex and peptide concentrations for 2 hours and incubated in fresh media for 24 
hours. Following incubation, supernatant was collected for cytokine analysis and an LDH assay was 
used to quantify cell viability. Polyplexes showed no significant toxicity except in TNFα-stimulated 
HCAVSMCs at the highest concentration tested (Appendix C). Furthermore, polyplexes formulated 
with the YARA cell penetrating peptide alone demonstrated significantly more toxicity than the YARA-
MK2i polyplexes in both TNFα and ANG II-stimulated HCAVSMCs.  
An enzyme-linked immunosorbent assay was performed on collected supernatants to 
quantify interleukin-6 (IL-6) secretion and TNFα production in TNFα and ANG II-stimulated 
A 
B 
C 
D 
E 
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HCAVSMCs, respectively. Both IL-6 and TNFα are inflammatory cytokines that are activated 
downstream of MK2 and, thus, provide indirect measure of MK2 inhibition [6, 47, 48]. Polyplexes 
were found to significantly inhibit IL-6 secretion in TNFα-stimulated HCAVSMCs at all concentrations 
in a dose-dependent manner compared to the untreated control (see fig. 9). Polyplexes were also 
found to significantly enhance YARA-MK2i-mediated inhibition of IL-6 compared to the YARA-MK2i 
peptide alone at concentrations of 10 and 100 μM. Furthermore, polyplexes without the therapeutic 
MK2i sequence did not reduce IL-6 secretion compared to the untreated control, indicating that the 
enhanced inhibition of IL-6 by polyplexes is mediated by enhanced delivery of the therapeutic MK2i 
peptide sequence. 
 
Figure 9 – Polyplex-mediated inhibition of IL-6 production: Increase in IL-6 production 
(compared to untreated control) in HCAVSMCs stimulated with TNFα for 6 hours, treated for 
two hours with polyplexes (containing the YARA-MK2i sequence or the YARA CPP alone) or 
the YARA-MK2i peptide alone and cultured for 24 hours in fresh media. All data is normalized 
to cell number as determined by an LDH assay. NT = no treatment. *p<0.05 compared to NT 
+ TNFα group, **p<0.01 compared to NT + TNFα group, $ p<0.05 compared to MK2i at the 
same concentration, 
$$
 p<0.05 compared to CPP polyplexes at the same concentration, n = 4. 
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Polyplexes were also found to significantly inhibit TNFα secretion in ANG II-stimulated 
HCAVSMCs at all concentrations in a dose-dependent manner (see fig. 10). Measurement of TNFα 
secretion in ANG II-stimulated HCAVSMCs proved to be a more robust readout of polyplex activity 
relative inhibition of IL-6 production in response to TNFα. Polyplexes demonstrated significantly more 
YARA-MK2i-mediated inhibition of TNFα compared to the YARA-MK2i peptide alone at all 
concentrations, with a 10 μM dose of polyplex having the equivalent inhibitory effect of 100 μM 
YARA-MK2i peptide alone. Furthermore, polyplexes made with a poly(acrylic acid) as a vehicle 
control did not demonstrate any enhancement in YARA-MK2i mediated inhibition of TNFα production. 
 
 
Figure 10 – Polyplex-mediated inhibition of TNFα production: TNFα production in 
HCAVSMCs stimulated with ANG II for 6 hours, treated for two hours with PPAA polyplexes, 
AA Polyplexes or the fusion MK2i peptide alone and cultured for 24 hours in fresh media. All 
data is normalized to cell number as determined by an LDH assay. Data for CPP polyplexes 
is not shown as all CPP polyplexes were found to upregulate TNFα production compared to 
the NT + TNFα group. NT = no treatment. *p<0.05 compared to NT + TNFα group, 
$ 
p<0.05 
compared to MK2i at the same concentration, 
$$ 
p<0.05 compared to AA polyplexes at the 
same concentration, n = 4. 
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Polyplex Uptake and Intracellular Trafficking 
To study the effects of co-delivering a pH-responsive, endosomolytic polymer in conjunction 
with the YARA-MK2i peptide, a fluorescent carboxyfluorescein (FAM) label was conjugated to the 
YARA-MK2i peptide prior to formulating fluorescent polyplexes. Microscopic analysis revealed that 
initially the peptide alone is colocalized within endosomal compartments, however, polyplex treated 
cells demonstrate diffuse cytoplasmic fluorescence and decreased endo-lysosomal colocalization 
(see fig. 11B). Additionally, more intense fluorescence is noticeable in polyplex treated samples 
compared to peptide treated samples, which is indicative of increased uptake. At the 4 hours cells 
treated with polyplexes begin to show enlarged vesicles with diffuse green staining, indicative of 
active endosomal membrane destabilization and rupture. Punctate, colocalized staining remains in 
cells treated with the peptide alone out to 24 hours, whereas diffuse staining is apparent in polyplex 
treated samples out to 12 hours. These differences in endo-lysosomal colocalization can be 
quantified through the calculation of the Mander’s coefficient, M1, defined as the ratio of the summed 
intensities of pixels in the green image for which the intensity in the red channel is above zero (the 
percentage of green FAM fluorophore that overlaps the red lysotracker fluorophore, where a value of 
1 reflect 100% colocalization, see fig. 11A). The Mander’s coefficient calculated for polylex treated 
cells were significantly less than cells treated with the peptide alone at all time points, with the peptide 
alone demonstrating near 100% colocalization at all time points. Interestingly, polyplex treated 
sampled evinced a time-dependent increase in colocalization at 10 and 22 hours of incubation, 
indicating that the cytoplasmic half-life of the peptide/fluorescence is lower than the endosomal half-
life of the peptide/fluorescence, which could potentially be due to enzymatic degradation in the 
cytosol or introduction into a retrograde trafficking pathway. 
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Figure 11 – Microscopic analysis of polyplex uptake: (A) Calculated Mander’s coefficient, 
M1, defined as the ratio of the summed intensities of pixels in the green image for which the 
intensity in the red channel is above zero for HCAVSMCs treated for two hours with either 
fluorescently-labeled YARA-MK2i peptide or fluorescently-labeled polyplexes. YARA-MK2i 
dose = 25 μM for all samples. Values shown are the average n=3 separate images ± SEM. 
*p<0.05 compared to YARA-MK2i at the same time point, **p<0.01 compared to YARA-MK2i 
at the same time point (B) Representative fluorescence images used to quantify 
colocalization. The numbers on the left represent the amount of time the cells were incubated 
in fresh media following two hours of treatment, the gain for both the red and green channels 
was kept constant for all images obtained. 
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 To quantify cellular uptake and assess differences in the intracellular half-life of polyplex vs. 
peptide treated cells, HCAVSMCs were treated with equivalent concentrations of fluorescently-
labeled YARA-MK2i peptide or fluorescently-labeled polyplexes for 2 hours and then incubated for an 
additional 46 hours in fresh media. Flow cytometric analysis of cellular uptake and retention over time 
revealed significant differences (p<0.05) between polyplex and peptide treated cells (see fig. 12). 
Polyplex treated cells demonstrated a mean fluorescence 2 orders of magnitude higher than cells 
treated with the peptide alone or with AA polyplex vehicle controls despite being treated with the 
same concentration of fluorescently labeled peptide. The mean fluorescence intensity of peptide and 
AA polyplex treated samples decreased significantly over the 48 hours following the initial treatment, 
whereas PPAA polyplex treated samples still demonstrate robust fluorescence at 48 hours. These 
results indicate that both the peptide alone and AA polyplexes are exocytosed or degraded within the 
endo-lysosomal pathway. PPAA polyplex treated cells also show a decrease in fluorescence over 
time, but still demonstrate fluorescence at 48 hours that far exceeds the fluorescence seen at early 
time points in cells treated with the peptide alone or AA polyplexes. In order to more clearly represent 
the differences in retention of the peptide over time, an exponential model was used to quantify 
intracellular fluorescence half-lives for each treatment group as shown in equation 1: 
                  ( )     
    
Where No is the initial mean fluorescence intensity, and λ is the decay constant for the mean 
fluorescence intensity and can be used to calculate intracellular fluorescence half-life using equation 
2: 
                     ⁄  
   ( )
 
 
By calculating the intracellular fluorescence half-life the differences in cellular uptake and retention 
are more clearly demonstrated: polyplex treated cells have an initial mean fluorescence intensity of No 
=2,611 compared to No =28 and No =33 for YARA-MK2i and AA treated cells, representing difference 
of ~2 orders of magnitude in initial uptake. Furthermore, polyplexes yielded an intracellular half-life of 
   ⁄  = 117 hours compared to    ⁄  = 27 hours for both YARA-MK2i and AA Polyplex treated cells, 
signifying that polyplexes are not as prone to exocytosis and/or degradation in the endo-lysosomal 
pathway as the peptide alone. 
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Figure 12 – Cellular uptake and intracellular half-life: Plots of mean fluorescence intensity 
over time and histograms of fluorescence intensity over time for PPAA polyplexes (A,B), the 
YARA-MK2i peptide alone (C,D), and AA polyplexes (E,F). Exponential lines were fit to each 
data set in order to determine a fluorescence half-life for each treatment group. Mean 
Fluorescence Intensity values are reported as increase in MFI compared to untreated 
controls, n=3. 
 
Discussion 
Methods to enable the efficient intracellular delivery of peptide-based therapeutics are a 
potentially high-impact but relatively unmet need.  This shortcoming is primarily due to multiple 
delivery barriers that exist in terms of delivering biomacromolecular therapeutics, each of which must 
be addressed to optimize bioactivity.  In this work, a novel platform technology is presented that not 
only enhances the cellular uptake of a therapeutic peptide, but facilitates its escape from the endo-
lysosomal pathway while containing an inherent mechanism to simultaneously release the peptide in 
the desired micro-environment.  
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The RAFT synthesized PPAA polymer serves as the key component of this nanotechnology 
platform for intracellular peptide delivery. The carboxylic acid groups present in the PPAA repeating 
unit has a pKa ~6.7, causing it to become protonated and membrane-disruptive at pH values 
encountered in the endo-lysosomal pathway as shown in fig. 9a. [49]. These carboxylic acid groups 
are deprotonated at pH values above the pKa of 6.7, rendering the polymer anionic at slightly basic 
pH values. This anionic behavior allows for electrostatic complexation with cationic peptides due to 
the presence of primary amines in specific amino acid side chains (pKa ~9-12 depending on the 
amino acid) and results in well-defined nano-polyplexes as shown in figs 6-7. Most peptide based 
therapeutics utilize a cell penetrating peptide to facilitate cellular uptake, and the majority of these cell 
penetrating peptides are cationic in nature (e.g. oligoarginines, oligolysines, TAT, penetratin, etc.) [23, 
24, 50, 51]. As a result, this approach has the potential to serve as a platform technology for the 
intracellular delivery of a wide range of therapeutic peptides for a variety of applications. Furthermore, 
the electrostatic complexation of a cationic therapeutic and the anionic ‘smart’ polymer is reversible, 
allowing for ‘de-complexation’ and release of the peptide once the PPAA polymer becomes 
protonated due to electrostatic repulsion as shown in fig. 9B-E. 
 Shown in fig. 1 is the signaling pathway targeted for validation of this approach to 
intracellular peptide delivery, as MAPKAP Kinase II is active in the cytoplasm and nucleus, and, as a 
result, an antagonist must be delivered into the cytosol in order to optimize bioactivity. A highly-
specific, cell penetrant peptide antagonist of MK2 has been previously developed and proven to 
modulate VSMC phenotype and prevent intimal hyperplasia in human saphenous vein [52], but 
peptides utilizing this CPP sequence have been shown to become trapped in the endo-lysosomal 
pathway   [19]. However, through the incorporation of this cationic peptide into an endosomolytic 
nano-polyplex that contains an endosomolytic ‘smart’ polymer this endosomal entrapment can be 
overcome as seen in the pH dependent membrane disruption seen in fig 8 and the diffuse staining 
pattern present in polyplex treated cells in fig. 11. Enhanced cytoplasmic delivery of this peptide 
should concomitantly increase its bioactivity and effectively reduce the half maximal inhibitory 
concentration, or IC50, of the therapeutic being delivered [53].  Figs 9-10 verify this endosomolytic 
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enhancement in bioactivity through well-established in vitro assays to assess VSMC phenotype [47, 
48]. 
It is well-established that peptides, not to mention other biomacromolecules like siRNA and 
DNA, suffer from poor cellular uptake when administered alone. As a result, cell penetrating peptides, 
fusogenic peptides, or targeting ligands are utilized to facilitate/enhance cellular uptake [51]. Despite 
the fact that the fusion peptide utilized in this work contains a cell-penetrating peptide sequence, 
formulation into a nano-polyplex results in a much more significant increase in uptake as shown in 
figs. 11-12. This finding is interesting in that providing a net-positive charge typically facilitates 
optimal cellular uptake [54] [55], yet the polyplexes developed demonstrated a net negative charge as 
shown by ζ-potential measurements in fig. 6. Fluorescence measurements were also performed on 
the supernatant of treated cells to look at fluorescently labeled peptide or polyplexes left in solution, 
and a clear difference was noted that correlated with the differences in uptake seen through 
microscopy and flow cytometric analysis (data not shown). Furthermore, the buffering capacity of the 
polyplexes may provide a means of cargo protection, since more acidic environments are typically 
more prone to degrade biologic drugs. Once internalized, the duration of efficacy of the delivered 
peptide is dependent on rates of exocytosis, endo-lysosomal degradation, and cytoplasmic 
degradation. It is well established that free peptides in the cytosol are short-lived and rapidly broken 
down by intracellular proteolytic complexes (e.g. the ATP-dependent 26 S proteasome) [56]; our 
results suggest that complexation with the PPAA polymer may stabilize the YARA-MK2i peptide and 
help sustain its bioactivity.  Previous in vivo time course studies have shown that utilizing the YARA-
MK2i peptide will delay the onset of intimal hyperplasia in vein grafts, but only appears to delay the 
onset of intimal thickening by ~ 1 week [57]. However, as shown in fig. 12, the cellular half-life of the 
peptide is significantly prolonged through delivery in the form of an endosomolytic polyplex, and thus, 
may increase the duration of efficacy of the peptide when used in bypass grafting applications.  
It is hypothesized that when the nanotechnology presented here is translated in vivo, that the 
enhanced uptake and intracellular half-life demonstrated in vitro will results in optimized protein 
delivery that minimizes the dose of peptide required and will prolong the duration of efficacy of the 
treatment. However, further studies will be necessary to better understand the underlying mechanism 
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of enhanced uptake and to corroborate the increase in intracellular half-life seen in preliminary 
results. Furthermore, ex vivo and in vivo studies will be necessary to evaluate the clinical 
translatability of this approach as a platform technology for intracellular peptide delivery. 
 
Conclusion 
Well defined, pH-responsive, endosomolytic nano-polyplexes were successfully synthesized 
and utilized to enhance the intracellular delivery and endosomal escape of a therapeutic MK2 inhibitor 
peptide. The synthesized nano-polyplexes demonstrated a significantly enhanced ability to facilitate 
cellular uptake of a therapeutic peptide and conjointly enhance its intracellular half-life. Furthermore, 
the increase in cell uptake and cellular half-life correlated well with in vitro enhancement of peptide 
bioactivity. Due to the modular nature of this approach, these nano-polyplexes can be adapted to a 
number of cationic biomacromolecular drugs, serving as a platform technology that not only has 
potential as a high-impact clinical tool but also provides a logical approach to studying the effect of 
intracellular-acting therapeutics. Finally, the described technology shows therapeutic potential as a 
preventative treatment in vascular bypass grafting applications, and may also show promise as a 
treatment for a myriad of human diseases. 
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CHAPTER III 
 
ONGOING AND FUTURE WORK 
 
Elucidating Method of Polyplex Uptake and Intracellular Trafficking 
Based on the preliminary cellular uptake studies presented in Chapter II, polyplexes 
demonstrated a profound increase in cellular uptake that was not expected due to a slightly negative 
ζ-potential. However, this drastic discrepancy may be in part due to the pH-sensitivity of the 
fluorophore utilized. In order to provide a more accurate description of differences in cellular uptake 
and intracellular trafficking, an alternative fluorophore label can be used that does not exhibit pH-
sensitive fluorescence (i.e. Alexa488, which shows stable fluorescence at pH values ranging from 4-
10). Fluorescence microscopy and flow cytometry studies will be repeated with an alternative 
fluorophore in order to corroborate the enhanced cellular uptake noted. Furthermore, the ratio in 
fluorescence intensity between pH-sensitive and a pH-insensitive fluorophores can be used as an 
indicator of the subcellular pH distribution encountered by the internalized therapeutics [58].  In order 
to more fully understand the underlying uptake mechanism that results in such a drastic differences in 
cellular uptake, a variety of cellular uptake assays that utilize inhibitors of specific cellular processes 
can be used to elucidate the mechanism of polyplex uptake [59]. Furthermore, plasmids containing a 
promotor sequence specific to various intracellular trafficking pathways can be used to transfect and 
monitor cells that are actively trafficking peptides delivered in polyplex form [19]. These studies will be 
key to understanding the mechanism of increased uptake and modulation of intracellular trafficking 
facilitated by these pH-responsive nano-polyplexes. 
 
Quantifying Duration of Efficacy 
Initial results indicate that the use of endosomolytic polyplexes to deliver a therapeutic 
peptide not only enhances uptake but increase the intracellular half-life of the therapeutic. This 
increase in intracellular half-life may potentially result in an increase in the duration of efficacy of the 
treatment. The duration of efficacy of these treatments can be more fully assayed through time 
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course studies that extend beyond the time points used in this work. Microscopic analysis of uptake 
and flow cytometric studies can be utilized to provide a more complete picture of peptide uptake, 
exocytosis, and degradation. Furthermore, pulse-chase in vitro assays, such as the inflammatory 
cytokine analyses performed in this work, can be adapted to provide a more thorough understanding 
of the temporal dynamics of peptide bioactivity.  
 
Ex Vivo and In Vivo Testing 
 Vascular and molecular biologist have made tremendous advances in understanding and 
treating vascular pathologies like coronary heart disease. This body of work presents a novel 
therapeutic approach that can potentially be translated into clinical use for the treatment of vessels 
used in bypass grafting procedures. To evaluate the potential of this technology ex vivo assays can 
be utilized to assess polyplex mediated vasorelaxation of human saphenous vein explants. 
Furthermore, human saphenous vein explants can be utilized in an organ culture model to assess the 
potential of the developed polyplexes to inhibit intimal hyperplasia in human tissue. Upon validation of 
therapeutic efficacy, a more robust rabbit carotid interposition in vivo model will be used to verify 
treatment efficacy in a clinically relevant vascular bypass grafting application 
 
Adaptation to Other Therapeutics and Applications 
 This drug delivery approach has demonstrated the potential to be utilized as a platform 
technology to facilitate intracellular peptide delivery, but the applicability of this approach to other 
peptide-based drugs and other applications has yet to be validated. The YARA-MK2i peptide 
described may be beneficial for a number of disease states including but not limited to asthma [60], 
inflammatory disease [60], Alzheimer’s disease [61, 62], cancer [63], and rheumatoid arthritis [64]. 
Thus, a library of endosomolytic nano-polyplexes containing a variety of different peptide-based 
therapeutics can be synthesized and characterized in order to determine the utility of this approach as 
a platform technology. In addition, this approach enables the topical or local treatment of target 
tissues, but does not allow for intravenous administration of a peptide-based drug. In order to 
facilitate hemocompatibility and prolong circulatory half-life, various other polyplex/nano-carrier 
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design schemes can be tested that utilize the same endosomolytic ‘smart’ polymer technology. For 
instance, a diblock copolymer containing the pH-responsive poly(propylacrylic acid) ‘smart’ polymer 
and a biocompatible, hydrophilic block [e.g. poly(ethylene glycol)  (PEG) or poly(hydroxypropyl) 
methacrylamide (HPMA)] could potentially be utilized to formulate micellar nanoparticles that contain 
electrostatically-complexed biomacromolecular therapeutics in the pH-responsive core of the 
construct.  
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APPENDIX 
Appendix A:  PPAA GPC analysis 
 
Supplementary Figure 1:  GPC chromatogram of poly(propylacrylic acid) (PPAA) 
homopolymer in DMF. The trace shows UV absorbance at the characteristic absorption peak 
of the trithiocarbonate moiety (310 nm) present in the 4-cyano-4-(ethylsulfanylthiocarbonyl) 
sulfanylvpentanoic acid (ECT) chain transfer agent utilized in the polymerization. MW = 
22,010, PDI =1.471, dη/dC = 0.087 (mL/g). 
 
 
Supplementary Figure 2:  GPC chromatogram of poly(acrylic acid) (AA) homopolymer in 
DMF. The trace shows UV absorbance at the characteristic absorption peak of the 
trithiocarbonate moiety (310 nm) present in the 4-cyano-4-(ethylsulfanylthiocarbonyl) 
sulfanylvpentanoic acid (ECT) chain transfer agent utilized in the polymerization. MW = 
10,830, PDI =1.273, dη/dC = 0.09 (mL/g). 
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Appendix B:  
1
H NMR Spectra 
 
Supplementary Figure 3:  
1
H NMR spectrum of poly(propylacrylic acid) (PPAA) 
homopolymer in D6MSO. Molecular weight was determined by comparing the area of peaks 
associated with the chain transfer agent (i.e. peak b) to peaks associated propylacrylic acid 
(i.e. peak c): Degree of polymerization = 190, MW = 21,950 g/mol). 
 
 
Supplementary Figure 4:  
1
H NMR spectrum of poly(acrylic acid) (AA) homopolymer in 
D6MSO. Molecular weight was determined by comparing the area of peaks associated with 
the chain transfer agent (i.e. peaks h,i) to peaks associated with acrylic acid (i.e. peak e): 
Degree of polymerization = 106, MW = 7,640 g/mol). 
 
a 
c 
b 
e 
d 
f 
g i 
h 
j c 
b 
f,e 
d,a 
H2O 
k 
D6MSO 
i,j 
36 
Appendix C:  Polyplex Cytotoxicity 
 
Supplementary Figure 5:  Cell viability in HCAVSMCs stimulated with TNFα for 6 hours, 
treated for two hours with polyplexes (containing the full fusion sequence or the CPP alone) 
or the fusion MK2i peptide and cultured for 24 hours in fresh media. NT = no treatment. 
*p<0.01 compared to NT + TNFα group, n = 4. 
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Supplementary Figure 6:  Cell viability in HCAVSMCs stimulated with 10 μM ANG II for 6 
hours, treated for two hours with polyplexes (containing the full fusion sequence with PPAA, 
the full fusion sequence with AA, or the CPP alone) or the fusion MK2i peptide and cultured 
for 24 hours in fresh media. NT = no treatment. *p<0.01 compared to NT – ANG II group, n = 
4. 
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